Position-specific chemical modification of siRNAs reduces “off-target” transcript silencing
Aimee L. Jackson(Miragen Therapeutics (United States)), Peter S. Linsley(Bristol-Myers Squibb (Germany))
Cited by 785
Related Papers
CTLA-4 is a second receptor for the B cell activation antigen B7.
|The Journal of Experimental Medicine|1991|1.7k
Rational Development of LEA29Y (belatacept), a High-Affinity Variant of CTLA4-Ig with Potent Immunosuppressive Properties
|American Journal of Transplantation|2005|708
Cobomarsen, an oligonucleotide inhibitor of miR‐155, co‐ordinately regulates multiple survival pathways to reduce cellular proliferation and survival in cutaneous T‐cell lymphoma
|British Journal of Haematology|2018|310
Complementarity determining region 1 (CDR1)- and CDR3-analogous regions in CTLA-4 and CD28 determine the binding to B7-1.
|The Journal of Experimental Medicine|1994|246
Covalent Dimerization of CD28/CTLA-4 and Oligomerization of CD80/CD86 Regulate T Cell Costimulatory Interactions
|Journal of Biological Chemistry|1996|238